PD-1 Blockers

Nivolumab and pembrolizumab are monoclonal antibodies that block the programmed death-1 receptor (PD-1, CD279), resulting in dis-inhibition of tumor-specific immune responses. Both are recently approved for use in the treatment of metastatic melanoma, and nivolumab as well for non-small cell lung ca...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cell Jg. 162; H. 5; S. 937
1. Verfasser:	Wolchok, Jedd D
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 27.08.2015
Schlagworte:	Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Clinical Trials as Topic Humans Lung Neoplasms - drug therapy Melanoma - drug therapy Programmed Cell Death 1 Receptor - antagonists & inhibitors Skin Neoplasms - drug therapy
ISSN:	1097-4172, 1097-4172
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!